Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBI-005 in Moderate to Severe Allergic Conjunctivitis
NCT02082899Phase 2Completed
- Sponsor
- Sesen Bio
- Start
- Feb 2014
- Primary completion
- Jun 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of isunakinra in allergic conjunctivitis (AC), sponsored by Sesen Bio. Started Feb 2014; status: completed.
02
Drugs
isunakinra
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT02082899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082899.